Comparative study between obstetric antiphospholipid syndrome and obstetric morbidity related with antiphospholipid antibodies
Copyright © 2017 Elsevier España, S.L.U. All rights reserved..
BACKGROUND AND OBJECTIVES: To compare clinical, laboratory, treatment and live birth rate data between women with aPL-related obstetric complications (OMAPS) not fulfilling the Sydney criteria and women fulfilling them (OAPS).
MATERIALS AND METHODS: Retrospective and prospective multicentre study. Data comparison between groups from The European Registry on Antiphospholipid Syndrome included within the framework of the European Forum on Antiphospholipid Antibody projects.
RESULTS: 338 women were analysed: 247 fulfilled the Sydney criteria (OAPS group) and 91 did not (OMAPS group). In the OMAPS group, 24/91 (26.37%) fulfilled laboratory Sydney criteria (subgroup A) and 67/91 (74.63%) had a low titre and/or non-persistent aPL-positivity (subgroup B). Overall, aPL laboratory categories in OAPS vs. OMAPS showed significant differences: 34% vs. 11% (p<0.0001) for category I, 66% vs. 89% (p<0.0001) for category II. No differences were observed when current obstetric complications were compared (p=0.481). 86.20% of OAPS women were treated vs. 75.82% of OMAPS (p=0.0224), particularly regarding the LDA+LMWH schedule (p=0.006). No differences between groups were observed in live births, gestational, puerperal arterial and/or venous thrombosis.
CONCLUSIONS: Significant differences were found among aPL categories between groups. Treatment rates were higher in OAPS. Both OAPS and OMAPS groups had similarly good foetal-maternal outcomes when treated. The proposal to modify OAPS classification criteria, mostly laboratory requirements, is reinforced by these results.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:151 |
|---|---|
| Enthalten in: |
Medicina clinica - 151(2018), 6 vom: 21. Sept., Seite 215-222 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Alijotas-Reig, Jaume [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 31.10.2019 Date Revised 31.10.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.medcli.2017.11.017 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM279382944 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM279382944 | ||
| 003 | DE-627 | ||
| 005 | 20231225022833.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.medcli.2017.11.017 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0931.xml |
| 035 | |a (DE-627)NLM279382944 | ||
| 035 | |a (NLM)29274674 | ||
| 035 | |a (PII)S0025-7753(17)30892-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Alijotas-Reig, Jaume |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Comparative study between obstetric antiphospholipid syndrome and obstetric morbidity related with antiphospholipid antibodies |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 31.10.2019 | ||
| 500 | |a Date Revised 31.10.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2017 Elsevier España, S.L.U. All rights reserved. | ||
| 520 | |a BACKGROUND AND OBJECTIVES: To compare clinical, laboratory, treatment and live birth rate data between women with aPL-related obstetric complications (OMAPS) not fulfilling the Sydney criteria and women fulfilling them (OAPS) | ||
| 520 | |a MATERIALS AND METHODS: Retrospective and prospective multicentre study. Data comparison between groups from The European Registry on Antiphospholipid Syndrome included within the framework of the European Forum on Antiphospholipid Antibody projects | ||
| 520 | |a RESULTS: 338 women were analysed: 247 fulfilled the Sydney criteria (OAPS group) and 91 did not (OMAPS group). In the OMAPS group, 24/91 (26.37%) fulfilled laboratory Sydney criteria (subgroup A) and 67/91 (74.63%) had a low titre and/or non-persistent aPL-positivity (subgroup B). Overall, aPL laboratory categories in OAPS vs. OMAPS showed significant differences: 34% vs. 11% (p<0.0001) for category I, 66% vs. 89% (p<0.0001) for category II. No differences were observed when current obstetric complications were compared (p=0.481). 86.20% of OAPS women were treated vs. 75.82% of OMAPS (p=0.0224), particularly regarding the LDA+LMWH schedule (p=0.006). No differences between groups were observed in live births, gestational, puerperal arterial and/or venous thrombosis | ||
| 520 | |a CONCLUSIONS: Significant differences were found among aPL categories between groups. Treatment rates were higher in OAPS. Both OAPS and OMAPS groups had similarly good foetal-maternal outcomes when treated. The proposal to modify OAPS classification criteria, mostly laboratory requirements, is reinforced by these results | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Anticuerpos antifosfolípido | |
| 650 | 4 | |a Antiphospholipid antibody | |
| 650 | 4 | |a Antiphospholipid syndrome | |
| 650 | 4 | |a Morbilidad obstétrica | |
| 650 | 4 | |a Obstetric morbidity, Incomplete obstetric antiphospholipid syndrome | |
| 650 | 4 | |a Registro | |
| 650 | 4 | |a Registry | |
| 650 | 4 | |a Síndrome antifosfolípido | |
| 650 | 4 | |a Síndrome antifosfolípido obstétrico incompleto | |
| 650 | 7 | |a Antibodies, Antiphospholipid |2 NLM | |
| 700 | 1 | |a Esteve-Valverde, Enrique |e verfasserin |4 aut | |
| 700 | 1 | |a Ferrer-Oliveras, Raquel |e verfasserin |4 aut | |
| 700 | 1 | |a LLurba, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Ruffatti, Amelia |e verfasserin |4 aut | |
| 700 | 1 | |a Tincani, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Lefkou, Elmina |e verfasserin |4 aut | |
| 700 | 1 | |a Bertero, Mª Tiziana |e verfasserin |4 aut | |
| 700 | 1 | |a Espinosa, Gerard |e verfasserin |4 aut | |
| 700 | 1 | |a de Carolis, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Rovere-Querini, Patrizia |e verfasserin |4 aut | |
| 700 | 1 | |a Lundelin, Krista |e verfasserin |4 aut | |
| 700 | 1 | |a Picardo, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Mekinian, Arsene |e verfasserin |4 aut | |
| 700 | 0 | |a EUROAPS Study Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Medicina clinica |d 1948 |g 151(2018), 6 vom: 21. Sept., Seite 215-222 |w (DE-627)NLM000359017 |x 1578-8989 |7 nnns |
| 773 | 1 | 8 | |g volume:151 |g year:2018 |g number:6 |g day:21 |g month:09 |g pages:215-222 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.medcli.2017.11.017 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 151 |j 2018 |e 6 |b 21 |c 09 |h 215-222 | ||